10-Q: Mustang Bio Narrows Losses, Boosts Cash Amid Strategic Shifts

Mustang Bio reported significantly reduced net losses and increased cash reserves for the nine months ended September 30, 2025, driven by cost-cutting measures and financing activities, despite ongoing going concern doubts and program changes.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $1.4 million from $14.8 million in the prior year.
• Cash and cash equivalents increased to $19.0 million as of September 30, 2025, from $6.8 million at December 31, 2024.
• Total stockholders' equity shifted from a deficit of $3.9 million at December 31, 2024, to positive equity of $9.8 million at September 30, 2025.
• Research and development expenses showed a credit of $1.2 million for the nine months ended September 30, 2025, compared to an expense of $8.2 million in the prior year, primarily due to cost-cutting, settlements of aged payables, and a gain from lease termination.
• General and administrative expenses decreased to $3.0 million for the nine months ended September 30, 2025, from $4.4 million in the prior year.
• The company completed a 1-for-50 reverse stock split on January 15, 2025.
• Received approximately $6.8 million in net proceeds from a February 2025 equity offering and $7.1 million from warrant exercises in July 2025.
• FDA granted Orphan Drug Designation for MB-108 (November 7, 2024) and MB-101 (July 7, 2025) for malignant glioma and recurrent diffuse and anaplastic astrocytoma/glioblastoma, respectively.
• Fred Hutch issued a notice of intent to terminate the CD20 License for MB-106 due to unpaid patent expenses and maintenance fees, with the company intending to negotiate termination for potential consideration.
• Substantial doubt exists about the company's ability to continue as a going concern for a period of one year after the date of issuance of these unaudited financial statements.

Sentiment

Score: 6

Explanation: The company demonstrated significant improvements in net loss and cash position, successfully raising capital and securing Orphan Drug Designations. However, the explicit "going concern" warning and the potential loss of the MB-106 program due to financial issues temper the overall sentiment. The strategic shifts and cost-cutting are necessary but highlight underlying financial fragility.

Positives

• Significant reduction in net loss for the nine months ended September 30, 2025, to $1.4 million from $14.8 million in the prior year.
• Cash and cash equivalents increased to $19.0 million as of September 30, 2025, from $6.8 million at December 31, 2024.
• Shift from a stockholders' deficit of $3.9 million to positive equity of $9.8 million.
• Operating cash outflow significantly reduced to $3.5 million for the nine months ended September 30, 2025, from $9.4 million in the prior year.
• Research and development expenses showed a credit of $1.2 million for the nine months ended September 30, 2025, due to cost-cutting, payable settlements, and a lease termination gain.
• General and administrative expenses decreased by $1.4 million for the nine months ended September 30, 2025.
• Successful capital raises through a February 2025 equity offering ($6.8 million net proceeds) and July 2025 warrant exercises ($7.1 million proceeds).
• FDA granted Orphan Drug Designation for MB-108 (malignant glioma) and MB-101 (recurrent diffuse and anaplastic astrocytoma/glioblastoma), providing incentives and potential market exclusivity.
• Regained compliance with Nasdaq's Bid Price Rule and Equity Rule.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months.
• Accumulated deficit remains high at $398.1 million as of September 30, 2025.
• Fred Hutch issued a notice of intent to terminate the CD20 License for MB-106 due to unpaid patent expenses and maintenance fees, potentially leading to the loss of this program.
• The company has not generated any revenue from its development stage products and does not know when, or if, it will generate any revenue.
• The company is a smaller reporting company and subject to 'baby shelf rules,' limiting capital raises through Form S-3 to one-third of its public float.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing increases risk and reduces control.
• The company is a majority-controlled subsidiary of Fortress Biotech, Inc., which could create conflicts of interest and results in annual share grants that dilute other stockholders.

Risks

• Incurred significant losses since inception and anticipate continued losses, may never achieve or maintain profitability.
• Substantial doubt regarding ability to continue as a going concern; will need to raise additional funding which may not be available on acceptable terms or at all.
• Failure to obtain necessary capital may force delays, limits, or termination of potential product candidates.
• No revenue from development stage products, and uncertainty of future revenue generation.
• Short operating history makes business and prospects difficult to evaluate.
• Future capital raising activities may dilute current stockholders, restrict operations, or cause relinquishment of proprietary rights.
• Future growth and success depend on ability to successfully develop and commercialize product candidates, which has not yet occurred.
• Future success is highly dependent on the successful development of CAR T technology and oncolytic virus product candidates.
• Preclinical and clinical development are highly speculative and carry high failure risk.
• May not receive required regulatory approvals for product candidates on projected timelines, if at all, leading to increased costs and delayed revenue.
• May not obtain desired labeling claims or favorable scheduling classifications for product promotion.
• Adverse side effects may necessitate abandoning or limiting product candidate development.
• Approved products may be subject to post-marketing requirements and increased regulatory scrutiny.
• Competitors may develop treatments for target indications, limiting commercial opportunity and profitability.
• If approved product candidates are not broadly accepted by the healthcare community, revenues will likely be limited.
• Successful product liability claims could incur substantial liability and limit commercialization.
• Reliance on third parties for preclinical studies and clinical trials, with risks of unsatisfactory performance or failure to meet deadlines.
• Reliance on third parties for manufacturing product candidates, increasing risk of insufficient quantities or unacceptable costs.
• Reliance on clinical data and results obtained by third parties, which may prove inaccurate or unreliable.
• May need to license intellectual property from third parties, which may not be available or on commercially reasonable terms.
• Operating in a heavily regulated industry with unpredictable impact from future legislation or administrative actions.
• Subject to anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations.
• Subject to environmental, health and safety laws and regulations, with potential for fines or penalties.
• Inability to obtain and maintain sufficient patent protection could allow competitors to commercialize similar products.
• Dependence on licensors to maintain and enforce intellectual property rights covering certain product candidates.
• Risk of costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce own/licensors' rights.
• Disputes with licensors may affect ability to develop or commercialize product candidates.
• Fortress Biotech, Inc. controls a voting majority of common stock and has rights to significant annual share grants, resulting in dilution.
• Agreements with Fortress may not have been on terms as favorable as from unaffiliated third parties.
• Shared directors with Fortress could create conflicts of interest.
• Risk of securities class action litigation.
• Market price for common stock has been volatile and may continue to fluctuate or decline.
• Catastrophic disaster could damage facilities or cause loss of key data.
• Reliance on information technology; internet or internal computer system failures, cyber-attacks, or security compromises could harm business.
• Employees, consultants, or third-party partners may engage in misconduct or improper activities.
• Inability to attract and retain key personnel.
• Growth subject to economic and geopolitical conditions.
• Business could be adversely affected by health pandemics or epidemics.
• Previously failed to satisfy Nasdaq continued listing rules; risk of delisting.

Future Outlook

The company expects to incur substantial expenses for the foreseeable future relating to research, development, and commercialization of its potential products. It will require substantial additional financing through equity and/or debt offerings, collaborations, or licensing arrangements to fully develop and commercialize its product candidates. The company is exploring the possibility of initiating an investigator-sponsored single-institution clinical trial for MB-109 in the second quarter of 2026. Discussions are ongoing with Fred Hutch regarding the potential termination of the MB-106 program.

Management Comments

• "We expect to incur substantial expenses for the foreseeable future relating to research, development and commercialization of our potential products."
• "There exists substantial doubt about our ability to continue as a going concern."
• "We are currently exploring with COH and Nationwide the possibility of conducting an investigator-sponsored single-institution trial under the COH IND to treat patients with IL13R2+ recurrent GBM and high-grade astrocytoma with MB-109 that could potentially be initiated in the second quarter of 2026."
• "Because cell processing for MB-101 will revert back to COH... we believe that it is reasonable to assume that the FDA will not require a lead-in cohort... the first patient enrolled will receive combination therapy, which will represent a considerable savings of time and money."
• "We are in ongoing discussions with Fred Hutch regarding potential termination of this program [MB-106]."

Industry Context

Mustang Bio operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on CAR T and oncolytic virus therapies for difficult-to-treat cancers and autoimmune diseases. The granting of Orphan Drug Designations for MB-101 and MB-108 aligns with a broader industry trend of seeking regulatory incentives for therapies addressing rare diseases with unmet medical needs. The challenges faced in securing ongoing funding and managing clinical programs, as evidenced by the 'going concern' warning and the potential termination of the MB-106 program, are common for clinical-stage biotech companies heavily reliant on external capital and successful trial outcomes. The strategic shift towards investigator-sponsored trials and cost-cutting measures reflects the intense pressure on smaller biotechs to conserve capital and de-risk development pathways in a challenging economic environment.

Comparison to Industry Standards

• The company's significant reduction in net loss and operating cash burn, alongside a substantial increase in cash reserves, indicates effective cost management and successful capital raising efforts, which are critical for clinical-stage biotechs often characterized by high burn rates.
• The 'going concern' warning is a common disclosure for early-stage biopharmaceutical companies that have not yet commercialized products and rely on external financing, similar to many peers in the development phase.
• The receipt of Orphan Drug Designations for MB-101 and MB-108 is a positive development, offering market exclusivity and incentives, a strategy frequently pursued by companies like Bluebird Bio or Sarepta Therapeutics for rare disease indications to enhance commercial viability.
• The potential termination of the MB-106 program due to unpaid fees highlights the financial pressures and strategic re-prioritization common in the biotech sector, where companies must make difficult decisions about pipeline assets based on funding and progress, akin to recent program discontinuations seen at companies like Agenus or Kura Oncology.
• The reliance on academic institutions (City of Hope, Fred Hutch, Nationwide Children's Hospital) for early-stage research and clinical trials is a standard model for many emerging biotechs, leveraging specialized expertise and infrastructure.

Corporate Governance

Related Party Transactions

• Mustang Bio is a majority-controlled subsidiary of Fortress Biotech, Inc. (Fortress).
• Management Services Agreement with Fortress: Expenses of $0.1 million for the three months and $0.4 million for the nine months ended September 30, 2025, recorded 50% in R&D and 50% in G&A.
• Founders Agreement with Fortress: Fortress receives a grant of shares equal to 2.5% of gross equity or debt financing. For the three months ended September 30, 2025, 59,334 shares were issued, resulting in $0.2 million expense. For the nine months, 127,140 shares were issued, resulting in $0.4 million expense.
• Annual Stock Dividend to Fortress: On January 1, 2025, 69,046 shares of common stock were issued to Fortress, representing 2.5% of fully-diluted outstanding equity as of December 31, 2024, valued at approximately $0.6 million.
• Payables and Accrued Expenses Related Party: Fortress pays for certain expenses on behalf of the company, recorded as expenses and within related party payables.
• Headquarters relocation: Following lease termination, headquarters moved to office space leased by Fortress, with Fortress allocating a portion of rent and office costs monthly to Mustang Bio.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises and annual share grants to Fortress. The reverse stock split reduced the number of shares outstanding. The "going concern" warning poses a significant risk to investment value. Improved financial metrics (reduced loss, increased cash, positive equity) are positive but must be weighed against ongoing risks.
• Employees: Workforce reductions in 2024 and termination of the Plantation Street Facility lease indicate a smaller operational footprint and potential job insecurity.
• Customers (future patients): The potential termination of the MB-106 program could mean a loss of a potential treatment option. Continued development of MB-109 offers hope for patients with malignant brain tumors.
• Creditors: The "going concern" warning indicates increased risk for creditors, though the improved cash position and reduced liabilities offer some short-term stability.
• Licensors (Fred Hutch, COH, Nationwide): The dispute with Fred Hutch over unpaid fees for the CD20 License highlights potential strain in licensing relationships. Continued collaboration with COH and Nationwide for MB-109 is crucial.

Next Steps

• Raise additional financing through equity and/or debt offerings, collaborations, and licensing arrangements.
• Negotiate terms for the termination of the CD20 License with Fred Hutch in exchange for potential consideration.
• Explore initiating an investigator-sponsored single-institution clinical trial for MB-109 at City of Hope in the second quarter of 2026.
• Continue to assess patients for long-term safety in completed Phase 1 clinical trials for MB-101, MB-108, and MB-106.
• Manage compliance with Nasdaq's continued listing rules, being under mandatory monitoring for one year.

Key Dates

Recommendation

Mustang Bio has shown significant improvements in its financial health, drastically reducing net losses and increasing cash reserves through successful capital raises and aggressive cost-cutting measures, including the termination of a facility lease. The shift to positive stockholders' equity is a notable achievement. However, the explicit 'substantial doubt about its ability to continue as a going concern' remains a critical overhang, indicating ongoing financial fragility and reliance on future capital. The potential loss of the MB-106 program due to a dispute with Fred Hutch is a setback for its pipeline. While Orphan Drug Designations for MB-101 and MB-108 are positive, the company is still in early clinical stages with no commercial products. The 'baby shelf rules' limit future capital raising flexibility. Given the improved financial performance but persistent high-risk profile and early-stage pipeline, a 'hold' recommendation is appropriate. Investors should monitor progress on future financing, clinical trial advancements, and the resolution of the MB-106 program, as well as the company's ability to address the going concern issue.

Keywords

Mustang Bio, MBIO, 10-Q, Quarterly Report, Biopharmaceutical, CAR T therapy, Oncolytic virus, Cancer treatment, Autoimmune diseases, Glioblastoma, Astrocytoma, MB-101, MB-108, MB-109, MB-106, Orphan Drug Designation, Financial results, Net loss, Cash position, Equity offering, Warrant exercise, Going concern, Fortress Biotech, Clinical trials, Drug development, Regulatory approval, Intellectual property, Nasdaq listing, Risk factors, Biotech finance